Retraction: Expression of USP22 and Survivin is an indicator of malignant behavior in hepatocellular carcinoma (International Journal of Oncology (2015) 47 (2208-2216) DOI: 10.3892/ijo.2015.3214);Expression of USP22 and survivin is an indicator of malignant behavior in hepatocellular carcinoma

International Journal of Oncology

Volumn 47, Issue 6, 2015, Pages 2208-2216

  Tang, Bo ^a   Liang, Xingsi ^a   Tang, Fang ^a   Zhang, Jing ^a   Zeng, Sien ^a   Jin, Shengjian ^a   Zhou, Lihua ^a   Kudo, Yasusei ^b   Qi, Guangying ^a  

^a GUILIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Cell cycle; Hepatocellular carcinoma; Survivin; USP22

Indexed keywords

CYCLIN B; DEUBIQUITINASE; PROTEIN P21; SMALL INTERFERING RNA; SURVIVIN; UBIQUITIN SPECIFIC PROTEASE 22; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; THIOL ESTER HYDROLASE; TUMOR MARKER; USP22 PROTEIN, HUMAN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL DIFFERENTIATION; CELL DIVISION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; GENE SILENCING; GENETIC TRANSFECTION; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; TUMOR CELL LINE; YOUNG ADULT;

ADULT; AGED; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; THIOLESTER HYDROLASES; TRANSFECTION; YOUNG ADULT;

EID: 84982743591     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2023.5485     Document Type: Erratum

References (37)

1. El-Serag HB: Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology 127(Suppl 1):S27-S34, 2004.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917, 2010.
3. Jin F, Xiang YB and Gao YT: Cancer survival in Shanghai, People's Republic of China. IARC Sci Publ 145:37-50, 1998.
4. Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM and Baek KH: The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns 6:277-284, 2006.
5. Zhang XY, Varthi M, Sykes SM, Phillips C, Warzecha C, Zhu W, Wyce A, Thorne AW, Berger SL and McMahon SB: The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell 29:102-111, 2008.
6. Zhang XY, Pfeiffer HK, Thorne AW and McMahon SB: USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle 7:1522-1524, 2008.
7. Liu Y, Yang Y, Xu H and Dong X: Implication of USP22 in the regulation of BMI-1, c-Myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas. Diagn Mol Pathol 19:194-200, 2010.
8. Zhang Y, Yao L, Zhang X, Ji H, Wang L, Sun S and Pang D: Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin Oncol 137:1245-1253, 2011.
9. Tang B, Tang F, Li B, Yuan S, Xu Q, Tomlinson S, Jin J, Hu W and He S: High USP22 expression indicates poor prognosis in hepatocellular carcinoma. Oncotarget 6:12654-12667, 2015.
10. Atanassov BS, Evrard YA, Multani AS, Zhang Z, Tora L, Devys D, Chang S and Dent SY: Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance. Mol Cell 35:352-364, 2009.
11. Atanassov BS and Dent SY: USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep 12:924-930, 2011.
12. Uren AG, Pakusch M, Hawkins CJ, Puls KL and Vaux DL: Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proc Natl Acad Sci USA 93:4974-4978, 1996.
13. Yang D, Welm A and Bishop JM: Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA 101:15100-15105, 2004.
14. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921, 1997.
15. Peters JM: The anaphase promoting complex/cyclosome: A machine designed to destroy. Nat Rev Mol Cell Biol 7:644-656, 2006.
16. Li Z, Pei XH, Yan J, Yan F, Cappell KM, Whitehurst AW and Xiong Y: CUL9 mediates the functions of the 3M complex and ubiquitylates survivin to maintain genome integrity. Mol Cell 54:805-819, 2014.
17. Connell CM, Colnaghi R and Wheatley SP: Nuclear survivin has reduced stability and is not cytoprotective. J Biol Chem 283:3289-3296, 2008.
18. Glinsky GV: Death-from-cancer signatures and stem cell contribution to metastatic cancer. Cell Cycle 4:1171-1175, 2005.
19. Glinsky GV, Berezovska O and Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115:1503-1521, 2005.
20. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, et al: Epigenetic stem cell signature in cancer. Nat Genet 39:157-158, 2007.
21. Glinsky GV: Genomic models of metastatic cancer: Functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle 5:1208-1216, 2006.
22. Sowa ME, Bennett EJ, Gygi SP and Harper JW: Defining the human deubiquitinating enzyme interaction landscape. Cell 138:389-403, 2009.
23. Piao S, Ma J, Wang W, Liu Y, Zhang M, Chen H, Guo F, Zhang B and Guo F: Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma. Oral Oncol 49:796-801, 2013.
24. Ning J, Zhang J, Liu W, Lang Y, Xue Y and Xu S: Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer. Eur J Histochem 56:e46, 2012.
25. Piao S, Liu Y, Hu J, Guo F, Ma J, Sun Y and Zhang B: USP22 is useful as a novel molecular marker for predicting disease progression and patient prognosis of oral squamous cell carcinoma. PLoS One 7:e42540, 2012.
26. Liu YL, Jiang SX, Yang YM, Xu H, Liu JL and Wang XS: USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem Biophys 62:229-235, 2012.
27. Lin Z, Yang H, Kong Q, Li J, Lee SM, Gao B, Dong H, Wei J, Song J, Zhang DD, et al: USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol Cell 46:484-494, 2012.
28. Honda R, Körner R and Nigg EA: Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 14:3325-3341, 2003.
29. Beardmore VA, Ahonen LJ, Gorbsky GJ and Kallio MJ: Survivin dynamics increases at centromeres during G2/M phase transition and is regulated by microtubule-attachment and Aurora B kinase activity. J Cell Sci 117:4033-4042, 2004.
30. Peroukides S, Bravou V, Alexopoulos A, Varakis J, Kalofonos H and Papadaki H: Survivin overexpression in HCC and liver cirrhosis differentially correlates with p-STAT3 and E-cadherin. Histol Histopathol 25:299-307, 2010.
31. Morinaga S, Nakamura Y, Ishiwa N, Yoshikawa T, Noguchi Y, Yamamoto Y, Rino Y, Imada T, Takanashi Y, Akaike M, et al: Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. Oncol Rep 12:1189-1194, 2004.
32. Qi G, Kudo Y, Ando T, Tsunematsu T, Shimizu N, Siriwardena SB, Yoshida M, Keikhaee MR, Ogawa I and Takata T: Nuclear Survivin expression is correlated with malignant behaviors of head and neck cancer together with Aurora-B. Oral Oncol 46:263-270, 2010.
33. Qi G, Tuncel H, Aoki E, Tanaka S, Oka S, Kaneko I, Okamoto M, Tatsuka M, Nakai S and Shimamoto F: Intracellular localization of survivin determines biological behavior in colorectal cancer. Oncol Rep 22:557-562, 2009.
34. Tuncel H, Shimamoto F, Kaneko Guangying Qi H, Aoki E, Jikihara H, Nakai S, Takata T and Tatsuka M: Nuclear Aurora B and cytoplasmic survivin expression is involved in lymph node metastasis of colorectal cancer. Oncol Lett 3:1109-1114, 2012.
35. Hori M, Miki T, Okamoto M, Yazama F, Konishi H, Kaneko H, Shimamoto F, Ota T, Temme A and Tatsuka M: The detergentsoluble cytoplasmic pool of survivin suppresses anoikis and its expression is associated with metastatic disease of human colon cancer. PLoS One 8:e55710, 2013.
36. Acquati S, Greco A, Licastro D, Bhagat H, Ceric D, Rossini Z, Grieve J, Shaked-Rabi M, Henriquez NV, Brandner S, et al: Epigenetic regulation of survivin by Bmi1 is cell type specific during corticogenesis and in gliomas. Stem Cells 31:190-202, 2013.
37. Bhattacharyya J, Mihara K, Ohtsubo M, Yasunaga S, Takei Y, Yanagihara K, Sakai A, Hoshi M, Takihara Y and Kimura A: Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression. Cancer Sci 103:34-41, 2012.